Share chart Terns Pharmaceuticals, Inc.
Extended chart
Simple chart
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., биофармацевтическая компания на клинической стадии, разрабатывает низкомолекулярные монотерапевтические препараты и комбинированные препараты для лечения неалкогольного стеатогепатита (НАСГ) и других хронических заболеваний печени. Он разрабатывает TERN-101, агонист фарнезоидных X рецепторов, не являющихся желчными кислотами, распределяемыми в печени, который проходит фазу 2а клинических испытаний для лечения НАСГ; и TERN-201, ингибитор протеина-1 сосудистой адгезии, который проходит фазу 1 клинических испытаний для лечения НАСГ. more detailsMain settings
IPO date
2021-02-05
ISIN
US8808811074
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 302.64 | 1 |
| P/BV | 1.27 | 9 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -28.1 | 0 |
| ROE | -29.56 | 0 |
| ROIC | -29.68 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.0154 | 10 |
| Debt/Ratio | 0.0037 | 10 |
| Debt/Equity | 0.0039 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 0 | 0 |
| Yield Ebitda, % | 139.61 | 10 |
| Yield EPS, % | -37.57 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 3.93 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 3.7 $ | 3.93 $ | 4.1 $ | 6.22 % | 0 % | 0 % |
| Month | 2.94 $ | 2.88 $ | 4.1 $ | 33.67 % | 0 % | 0 % |
| Three month | 2.3 $ | 2 $ | 4.1 $ | 70.87 % | 0 % | 0 % |
| Half a year | 4.52 $ | 2 $ | 6.05 $ | -13.05 % | 0 % | 0 % |
| Year | 7.95 $ | 2 $ | 11.23 $ | -50.57 % | 0 % | 0 % |
| 3 years | 4.01 $ | 1.87 $ | 13.26 $ | -2 % | 0 % | 0 % |
| 5 years | 0 $ | 1.5 $ | 27.25 $ | 0 % | 0 % | 0 % |
| 10 years | 0 $ | 1.5 $ | 27.25 $ | 0 % | 0 % | 0 % |
| Year to date | 4.06 $ | 2 $ | 5.75 $ | -3.2 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| Orbimed Advisors LLC. | 7 619 135 | 11.78 |
| Vivo Capital, LLC | 6 657 992 | 10.3 |
| Deep Track Capital, LP | 6 100 000 | 9.44 |
| Suvretta Capital Management, LLC | 5 837 126 | 9.03 |
| VR Adviser, LLC | 4 497 117 | 6.96 |
| Blackrock Inc. | 3 408 978 | 5.27 |
| FMR, LLC | 2 990 402 | 4.63 |
| Braidwell LP | 2 318 050 | 3.59 |
| Franklin Resources, Inc. | 2 307 834 | 3.57 |
| Vanguard Group Inc | 2 187 471 | 3.38 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Future Tech ETF | 0.06869 | -18.13 | 0.35 |
| Principal Healthcare Innovators ETF | 0.06869 | -3.92 | 0.35 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Dr. Emil T. Kuriakose M.D. | Chief Medical Officer | N/A | 1980 (45 years) |
| Ms. Amy L. Burroughs M.B.A. | CEO & Director | N/A | 1970 (55 years) |
| Dr. Mark Joseph Vignola Ph.D. | CFO & Treasurer | 402.15k | 1978 (47 years) |
| Ms. Elona Kogan Esq., J.D. | Chief Legal Officer | 1969 (56 years) | |
| Ms. Melita Sun Jung | Chief Business Officer | 1977 (48 years) | |
| Mr. Scott Harris | Chief Development Officer | ||
| Dr. Jeffrey R. Jasper Ph.D. | Senior Vice President of Research | ||
| Ms. Debra Sieminski | Senior Vice President of Medical Affairs | ||
| Ms. Pamela Danagher | Senior Vice President of Regulatory Affairs & Quality Assurance | ||
| Mr. David Eric Strauss | VP of Finance & Controller | 1986 (39 years) |
About company
Address: United States, Foster City, 1065 East Hillsdale Boulevard - Open in google maps, Open in yandex maps
Website: https://www.ternspharma.com
Website: https://www.ternspharma.com
